Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becoming increasingly fragmented as more biomarker-driven therapies enter the market. Nevertheless, owing to the limited size of these patient subpopulations, the immune checkpoint inhibitors, most notably Keytruda (Merck & Co.), continue to dominate the NSCLC market. Competition is set to intensify further over the forecast period as multiple immune checkpoint inhibitor-based combination therapies gain approval and enter clinical practice. In addition, a flurry of novel agents and regimens from different drug classes are in development for NSCLC, including ALK, MET, and RET inhibitors, immune checkpoint inhibitors, angiogenesis inhibitors, and therapeutic vaccines, all vying for a share of the increasingly crowded and competitive market.
Questions answered
- How are the drug-treatable populations defined in NSCLC? How do these differ in size, and will drug-treatment rates per population change over time?
- How will recent and expected market approvals shape the treatment landscape in first-line metastatic NSCLC? Which agents and combinations will dominate this commercially lucrative setting?
- What pipeline products are considered most promising, and what uptake and patient share could they secure in NSCLC? What key therapies are in earlier phases of development?
- What are the key market drivers and constraints in NSCLC, and how will the market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 interviews with experts and country-specific surveys with medical oncologists (~30 per country) who treat NSCLC.
Epidemiology: Diagnosed and recurrent incidence of adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.
Population segments in market forecast: Stage IB/II, stage III, first-line, second-line, and third-line for metastatic adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.
Emerging therapies: Phase III/PR: 41 drugs; coverage of select agents in Phase II and Phase I development.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- Q4 2022
- December 2022
- Q3 2022
- September 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2022
- Market outlook
- Key findings
- Major-market share of drug classes for NSCLC: 2021
- Major-market share of drug classes for NSCLC: 2031
- Key current therapies in NSCLC: population positioning
- Emerging therapies in NSCLC: population positioning
- NSCLC SWOT analysis
- Market drivers and constraints
- What factors are driving the market for NSCLC?
- What factors are constraining the market for NSCLC?
- Drug-treatable population share and major-market sales share in NSCLC: 2021
- Drug-treatable population share and major-market sales share in NSCLC: 2031
- Major-market sales of key therapies for NSCLC (excluding immune checkpoint inhibitors): 2021-2031
- Major-market sales of immune checkpoint inhibitors for NSCLC: 2021-2031
- Major-market share of immune checkpoint inhibitors in NSCLC, by patient population (all histologies): 2031
- Segment-specific trends
- Patient-share dynamics of key regimens in first-line metastatic NSCLC (adenocarcinoma), United States: 2021-2031
- Patient-share dynamics of key regimens in first-line metastatic NSCLC (squamous), United States: 2021-2031
- Patient-share dynamics of key therapies in first-line EGFR-positive metastatic NSCLC (adenocarcinoma), United States: 2021-2031
- ALK inhibitors
- Patient-share dynamics of key therapies in first-line ALK-positive metastatic NSCLC (adenocarcinoma), United States: 2021-2031
- Patient-share dynamics of immune checkpoint inhibitors in first-line metastatic NSCLC (adenocarcinoma), United States: 2021-2031
- Patient-share dynamics of key regimens in second-line metastatic NSCLC (adenocarcinoma), United States: 2021-2031
- Patient-share dynamics of key regimens in second-line metastatic NSCLC (squamous), United States: 2021-2031
- Patient-share dynamics of immune checkpoint inhibitors in second-line metastatic NSCLC (adenocarcinoma), United States: 2021-2031
- Patient-share dynamics of immune checkpoint inhibitors in third-line metastatic NSCLC (adenocarcinoma), United States: 2021-2031
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and pathophysiology
- Disease overview
- Disease pathophysiology
- Progression of NSCLC
- Anatomy and histology of NSCLC
- Natural history of NSCLC
- Timing of genetic changes in NSCLC
- Staging and classification
- Classification of NSCLC
- Staging of NSCLC
- Key pathways and drug targets
- Key pathways and drug targets for NSCLC
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods
- Sources used for diagnosed incidence of NSCLC
- Disease definition, methods, and sources used
- Diagnosed incident cases of NSCLC by histology: 2021-2031
- Disease definition
- Methods
- Sources used for stage distribution of NSCLC
- Disease definition, methods, and sources used
- Diagnosed incident cases of adenocarcinoma by stage at diagnosis: 2021-2031
- Diagnosed incident cases of squamous cell carcinoma by stage at diagnosis: 2021-2031
- Diagnosed incident cases of large-cell and other types of NSCLC by stage at diagnosis: 2021-2031
- Diagnosed incident cases of NOS NSCLC by stage at diagnosis: 2021-2031
- Disease definition
- Methods
- Sources used for recurrent incident cases of NSCLC
- Disease definition, methods, and sources used
- Recurrent incident cases of NSCLC by histology: 2021-2031
- Non-small-cell lung cancer patient flow
- Drug-treatable cases of adenocarcinoma NSCLC: 2021-2031
- Drug-treatable cases of large-cell, other, and NOS NSCLC: 2021-2031
- Drug-treatable cases of squamous cell NSCLC: 2021-2031
- Drug-treated cases of adenocarcinoma NSCLC: 2021-2031
- Drug-treated cases of large-cell, other, and NOS NSCLC: 2021-2031
- Drug-treated cases of squamous cell NSCLC: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for non-small-cell lung cancer
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for non-small-cell lung cancer
- Current treatments used for non-small-cell lung cancer
- Market events impacting the use of key current therapies in non-small-cell lung cancer
- Key results from select clinical trials investigating Tagrisso for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Tagrisso
- Key ongoing clinical trials of Tagrisso in the treatment of non-small-cell lung cancer
- Expert insight: Tagrisso
- Key results from select clinical trials investigating Exkivity for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Exkivity
- Key ongoing clinical trials of Exkivity in the treatment of non-small-cell lung cancer
- Expert insight: Exkivity
- Ongoing clinical development of erlotinib
- Key ongoing clinical trials of erlotinib in the treatment of non-small-cell lung cancer
- Lumakras / Lumykras
- Key results from select clinical trials investigating Lumakras / Lumykras for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Lumakras / Lumykras
- Key ongoing clinical trials of Lumakras / Lumykras in the treatment of non-small-cell lung cancer
- Expert insight: Lumakras / Lumykras
- Key results from select clinical trials investigating Krazati for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Krazati
- Key ongoing clinical trials of Krazati in the treatment of non-small-cell lung cancer
- Key results from select clinical trials investigating Alecensa for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Alecensa
- Key ongoing clinical trials of Alecensa in the treatment of non-small-cell lung cancer
- Expert insight: Alecensa
- Key results from select clinical trials investigating Alunbrig for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Alunbrig
- Key ongoing clinical trials of Alunbrig for the treatment of non-small-cell lung cancer
- Insight: Alunbrig
- Key results from select clinical trials investigating Lorbrena / Lorviqua for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Lorbrena / Lorviqua
- Key ongoing trials of Lorbrena / Lorviqua in the treatment of non-small-cell lung cancer
- Expert insight: Lorbrena / Lorviqua
- Advantages and disadvantages of Xalkori
- Ongoing clinical development of Xalkori
- Key ongoing clinical trials of Xalkori in the treatment of non-small-cell lung cancer
- Ongoing clinical development of Zykadia
- Expert insight: Zykadia
- Key results from select clinical trials investigating Tabrecta for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Tabrecta
- Key ongoing clinical trials of Tabrecta in the treatment of non-small-cell lung cancer
- Key results from select clinical trials investigating Tepmetko for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Tepmetko
- Key ongoing clinical trials of Tepmetko in the treatment of non-small-cell lung cancer
- Expert insight: MET inhibitors for non-small-cell lung cancer
- Key results from select clinical trials investigating Retevmo / Retsevmo for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Retevmo / Retsevmo
- Key ongoing clinical trials of Retevmo / Retsevmo in the treatment of non-small-cell lung cancer
- Gavreto
- Key results from select clinical trials investigating Gavreto for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Gavreto
- Key ongoing clinical trials of Gavreto in the treatment of non-small-cell lung cancer
- Expert insights: RET inhibitors
- Key results from select clinical trials investigating Rozlytrek for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Rozlytrek
- Key ongoing clinical trials of Rozlytrek in the treatment of non-small-cell lung cancer
- Expert insight: Rozlytrek
- Key results from select clinical trials investigating Keaytruda for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of non-small-cell lung cancer
- Expert insight: Keytruda
- Opdivo
- Key results from select clinical trials investigating Opdivo for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of non-small-cell lung cancer
- Opdivo combination therapies
- Key results from select clinical trials investigating Opdivo combination therapies for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Opdivo combination therapies
- Key ongoing clinical trials of Opdivo combination therapies in the treatment of non-small-cell lung cancer
- Expert insight: Opdivo and Yervoy combination therapy
- Key results from select clinical trials investigating Tecentriq for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Tecentriq
- Key ongoing clinical trials of Tecentriq in the treatment of non-small-cell lung cancer
- Expert insight: Tecentriq
- Key results from select clinical trials investigating Imfinzi for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Imfinzi
- Key ongoing clinical trials of Imfinzi in the treatment of non-small-cell lung cancer
- Expert insight: Imfinzi
- Key results from select clinical trials investigating Imfinzi for the treatment of non-small-cell lung cancer
- Expert insight: Imfinzi plus Imjudo
- Key results from select clinical trials investigating Libtayo for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Libtayo
- Key ongoing clinical trials of Libtayo in the treatment of non-small-cell lung cancer
- Expert insight: Libtayo
- Key results from select clinical trials investigating Enhertu for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Enhertu
- Key ongoing clinical trials of Enhertu in the treatment of non-small-cell lung cancer
- Rybrevant
- Key results from select clinical trials investigating Rybrevant for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Rybrevant
- Key ongoing clinical trials of Rybrevant in the treatment of non-small-cell lung cancer
- Expert insight: Rybrevant
- Ongoing clinical development of bevacizumab
- Key results from select clinical trials investigating Cyramza for the treatment of non-small-cell lung cancer
- Ongoing clinical development of Cyramza
- Advantages and disadvantages of Vargatef
- Ongoing clinical development of Abraxane
- Medical practice
- Localized stage I/II and resectable and unresectable stage III non-small-cell lung cancer
- First-line metastatic nonsquamous non-small-cell lung cancer
- First-line metastatic squamous non-small-cell lung cancer
- Second- and third-line metastatic nonsquamous non-small-cell lung cancer
- Second- and third-line metastatic squamous non-small-cell lung cancer
- Treatment guidelines
- Patient characteristics influencing drug selection
- Treatment decision tree for localized (stage I/II) non-small-cell lung cancer
- Treatment decision tree for locally advanced (stage III) non-small-cell lung cancer
- Treatment decision tree for metastatic (stage IV) nonsquamous non-small-cell lung cancer
- Treatment decision tree for BRAF-Mutation and ROS-1-positive metastatic (stage IV) nonsquamous non-small-cell lung cancer
- Treatment decision tree for RET-mutant and MET-mutant metastatic (stage IV) nonsquamous non-small-cell lung cancer
- Treatment decision tree for metastatic (stage IV) squamous non-small-cell lung cancer
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in non-small-cell lung cancer
- Top unmet needs in non-small-cell lung cancer: current and future attainment
- Drug pipeline
- Pipeline
- Regulatory milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for non-small-cell lung cancer
- Estimated market authorization dates of key emerging therapies for the treatment of non-small-cell lung cancer
- Key results from select clinical trials investigating lazertinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of lazertinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for lazertinib
- Expert insight: lazertinib
- Expectations for market authorization and sales opportunity of lazertinib in non-small-cell lung cancer
- Key results from select clinical trials investigating sunvozertinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of sunvozertinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for sunvozertinib
- Expectations for market authorization and sales opportunity of sunvozertinib in non-small-cell lung cancer
- Key results from select clinical trials investigating aumolertinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of aumolertinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for aumolertinib
- Expectations for market authorization and sales opportunity of aumolertinib in non-small-cell lung cancer
- Key results from select clinical trials investigating ensartinib for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for ensartinib
- Expectations for market authorization and sales opportunity of ensartinib in non-small-cell lung cancer
- Key results from select clinical trials investigating savolitinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of savolitinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for savolitinib
- Expert insight: savolitinib
- Expectations for market authorization and sales opportunity of savolitinib in non-small-cell lung cancer
- Key results from select clinical trials investigating JDQ-443 for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of JDQ-443 in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for JDQ-443
- Expert insight: emerging KRAS inhibitors
- Expectations for market authorization and sales opportunity of JDQ-443 in non-small-cell lung cancer
- Key results from select clinical trials investigating repotrectinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of repotrectinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for repotrectinib
- Expert insight: repotrectinib
- Expectations for market authorization and sales opportunity of repotrectinib in non-small-cell lung cancer
- Key results from select clinical trials investigating Bavencio for the treatment of non-small-cell lung cancer
- Key ongoing trials of Bavencio in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Bavencio
- Expert insight: use of Bavencio in the treatment of non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of Bavencio in non-small-cell lung cancer
- Key results from select clinical trials investigating tislelizumab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of tislelizumab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for tislelizumab
- Expectations for market authorization and sales opportunity of tislelizumab in non-small-cell lung cancer
- Key ongoing clinical trials of retifanlimab for the treatment of non-small-cell lung cancer
- Analysis of clinical development program for retifanlimab
- Expectations for market authorization and sales opportunity of retifanlimab in non-small-cell lung cancer
- Cosibelimab
- Key results from select clinical trials investigating cosibelimab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of cosibelimab in the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of cosibelimab in the treatment of non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of cosibelimab in non-small-cell lung cancer
- Key results from select clinical trials investigating sintilimab for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for sintilimab
- Expert insight: sintilimab
- Expectations for market authorization and sales opportunity of sintilimab in non-small-cell lung cancer
- Key results from select clinical trials investigating sugemalimab for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for sugemalimab
- Expectations for market authorization and sales opportunity of sugemalimab in non-small-cell lung cancer
- Key results from select clinical trials investigating Jemperli for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of Jemperli in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Jemperli
- Expectations for market authorization and sales opportunity of Jemperli in non-small-cell lung cancer
- Key results from select clinical trials investigating toripalimab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of toripalimab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for toripalimab
- Expectations for market authorization and sales opportunity of toripalimab in non-small-cell lung cancer
- Key results from select clinical trials investigating tiragolumab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of tiragolumab for the treatment of non-small-cell lung cancer
- Analysis of clinical development program for tiragolumab
- Expert insight: tiragolumab
- Expectations for market authorization and sales opportunity of tiragolumab in non-small-cell lung cancer
- Key results from select clinical trials investigating vibostolimab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of vibostolimab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for vibostolimab
- Expectations for market authorization and sales opportunity of vibostolimab in non-small-cell lung cancer
- Key ongoing clinical trials of ociperlimab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for ociperlimab
- Expectations for market authorization and sales opportunity of ociperlimab in non-small-cell lung cancer
- Key ongoing clinical trials of domvanalimab for the treatment of non-small-cell lung cancer
- Analysis of clinical development program for domvanalimab
- Expectations for market authorization and sales opportunity of domvanalimab in non-small-cell lung cancer
- Key results from select clinical trials investigating oleclumab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of oleclumab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for oleclumab
- Expectations for market authorization and sales opportunity of oleclumab in non-small-cell lung cancer
- Analysis of the clinical development program for monalizumab
- Expert insight: oleclumab and monalizumab in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of monalizumab in non-small-cell lung cancer
- Key results from select clinical trials investigating lifileucel for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of lifileucel in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for lifileucel
- Expert insights: the use of lifileucel in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of lifileucel in non-small-cell lung cancer
- Key results from select clinical trials investigating Lenvima for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of Lenvima in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Lenvima
- Expert insight: Lenvima
- Expectations for market authorization and sales opportunity of Lenvima in non-small-cell lung cancer
- Key results from select clinical trials investigating Cabometyx for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of Cabometyx in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Cabometyx
- Expert insight: Cabometyx
- Expectations for market authorization and sales opportunity of Cabometyx in non-small-cell lung cancer
- Key results from select clinical trials investigating sitravatinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of sitravatinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for sitravatinib
- Expectations for market authorization and sales opportunity of sitravatinib in non-small-cell lung cancer
- Key results from select clinical trials investigating plinabulin for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for plinabulin
- Expert insight: use of plinabulin in the treatment of non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of plinabulin in non-small-cell lung cancer
- Key ongoing clinical trials of Lynparza in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Lynparza
- Expert insight: Lynparza
- Expectations for market authorization and sales opportunity of Lynparza in non-small-cell lung cancer
- Key results from select clinical trials investigating Zejula for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of Zejula in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Zejula
- Expectations for market authorization and sales opportunity of Zejula in non-small-cell lung cancer
- Key results from select clinical trials investigating OSE-2101 for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for OSE-2101
- Expert insight: use of OSE-2101 in the treatment of non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of OSE-2101 in non-small-cell lung cancer
- Key results from select clinical trials investigating canakinumab for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of canakinumab in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for canakinumab
- Expert insight: canakinumab
- Expectations for market authorization and sales opportunity of canakinumab in non-small-cell lung cancer
- Key results from select clinical trials investigating nogapendekin alfa (N-803) for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of nogapendekin alfa (N-803) in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for nogapendekin alfa (N-803)
- Expectations for market authorization and sales opportunity of nogapendekin alfa (N-803) in non-small-cell lung cancer
- Key results from select clinical trials investigating tusamitamab ravtansine for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of tusamitamab ravtansine in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for tusamitamab ravtansine
- Expert insight: use of tusamitamab ravtansine in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of tusamitamab ravtansine in non-small-cell lung cancer
- Key results from select clinical trials investigating datopotamab deruxtecan for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of datopotamab deruxtecan in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for datopotamab deruxtecan
- Expectations for market authorization and sales opportunity of datopotamab deruxtecan in non-small-cell lung cancer
- Key results from select clinical trials investigating Trodelvy for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of Trodelvy in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for Trodelvy
- Expert insight: use of anti-TROP2 ADCs in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of Trodelvy in non-small-cell lung cancer
- Key results from select clinical trials investigating patritumab deruxtecan for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of patritumab deruxtecan in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for patritumab deruxtecan
- Expectations for market authorization and sales opportunity of patritumab deruxtecan in non-small-cell lung cancer
- Expert insight: use of patritumab deruxtecan in non-small-cell lung cancer
- Key results from select clinical trials investigating telisotuzumab vedotin for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of telisotuzumab vedotin in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for telisotuzumab vedotin
- Expert insight: use of telisotuzumab vedotin in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of telisotuzumab vedotin in non-small-cell lung cancer
- Key results from select clinical trials investigating pyrotinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of pyrotinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for pyrotinib
- Expectations for market authorization and sales opportunity of pyrotinib in non-small-cell lung cancer
- Key results from select clinical trials investigating poziotinib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of poziotinib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for poziotinib
- Expert insight: use of poziotinib in non-small-cell lung cancer
- Expectations for market authorization and sales opportunity of poziotinib in non-small-cell lung cancer
- Key results from select clinical trials investigating VS-6766 for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of VS-6766 in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for VS-6766
- Expectations for market authorization and sales opportunity of VS-6766 in non-small-cell lung cancer
- Key results from select clinical trials investigating defactinib for the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for defactinib
- Expectations for market authorization and sales opportunity of defactinib in non-small-cell lung cancer
- Key results of select clinical trials investigating ceralasertib for the treatment of non-small-cell lung cancer
- Key ongoing clinical trials of ceralasertib in the treatment of non-small-cell lung cancer
- Analysis of the clinical development program for ceralasertib
- Expectations for market authorization and sales opportunity of ceralasertib in non-small-cell lung cancer
- Early-phase pipeline analysis
- Select compounds in Phase II development for non-small-cell lung cancer
- Key findings
- Access and reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in NSCLC: United States
- General reimbursement environment: United States
- Key market access considerations in NSCLC: EU5
- General reimbursement environment: EU5
- Key market access considerations in NSCLC: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Non-small-cell lung cancer bibliography
- Key findings
Tiffany Chan, Ph.D., Healthcare Research & Data Analyst, Oncology. Prior to joining Clarivate, Dr. Chan worked as a postdoctoral researcher at the University of Oxford, where her research focused on the high-throughput screening of 177Lu-PSMA combination therapies for the treatment of prostate cancer. She obtained her Ph.D. in chemistry from Imperial College London, which is affiliated with the Imperial Centre of Excellence in Neurotechnology and the Department of Biomedical Engineering.
Arman Esfandiari, M.Res., Ph.D., is an analyst on the Oncology and Biosimilars teams at Clarivate. He has a long-standing interest in cancer therapeutics and holds a Ph.D. in cancer biology from Newcastle University. As a postdoctoral research fellow at the Northern Institute for Cancer Research and at University College London, he focused on the research and development of small-molecule inhibitors, DNA-damaging agents, and antibody-drug conjugates.